Anti-Hypertensive Drugs - Sweden

Sweden

In Sweden, the revenue generated in the Anti-Hypertensive Drugs market is projected to reach US$95.17m by the year 2024.
It is expected that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of -0.11%, leading to a market volume of US$94.65m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$12,290.00m in 2024.
Sweden is seeing a growing demand for innovative and sustainable anti-hypertensive drugs, as the country prioritizes healthcare advancements and environmental consciousness.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Sweden has been seeing a steady growth in recent years.

Customer preferences: Swedish customers have been increasingly concerned about their health and are more willing to invest in preventive medicine. This has led to a growing demand for Anti-Hypertensive Drugs, which are used to treat high blood pressure, a common health issue in Sweden.

Trends in the market: The market for Anti-Hypertensive Drugs in Sweden has been witnessing a shift towards generic drugs due to their lower cost compared to branded drugs. This has led to an increase in competition among drug manufacturers, which has resulted in lower prices for consumers. Additionally, there has been a growing trend towards online pharmacies, which offer convenience and competitive prices.

Local special circumstances: Sweden has a universal healthcare system, which means that the government plays a significant role in regulating the pharmaceutical industry. This has led to a focus on cost-effectiveness and the promotion of generic drugs. Additionally, the Swedish government has been investing in eHealth initiatives, which have made it easier for patients to access healthcare services online.

Underlying macroeconomic factors: Sweden has a high standard of living and a strong economy, which has led to a high level of healthcare spending. Additionally, the country has an aging population, which is more likely to require medication for chronic health conditions such as high blood pressure. The Swedish pharmaceutical market is also heavily regulated, which has led to a focus on cost-effectiveness and the promotion of generic drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.